Michael Burchmore
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 7
- HER2/EGFR in Cancer Research 6
- Cancer Treatment and Pharmacology 4
- Peptidase Inhibition and Analysis 3
-
- Monoclonal and Polyclonal Antibodies Research 2
- Co-authors
- Dennis J. Slamon (5 shared papers)Maureen Murphy (3 shared papers)Steven Shak (4 shared papers)Debu Tripathy (4 shared papers)Melody Cobleigh (4 shared papers)Louis Fehrenbacher (4 shared papers)William Novotny (4 shared papers)Lyndsay N. Harris (4 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)European Journal of Cancer (3 papers)Oncology (1 paper)Orthopedics (1 paper)PubMed (1 paper)
- Partner nations
- United StatesCanada
In The Last Decade
Michael Burchmore
9 papers receiving 2.0k citations
Michael Burchmore's Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 1.4k
- Radiology, Nuclear Medicine and Imaging 687
- Cancer Research 273
- Immunology and Allergy 63
- Genetics 83
Countries citing papers authored by Michael Burchmore
This map shows the geographic impact of Michael Burchmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Burchmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Burchmore more than expected).
Fields of papers citing papers by Michael Burchmore
This network shows the impact of papers produced by Michael Burchmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Burchmore. The network helps show where Michael Burchmore may publish in the future.
Co-authors
The 20 scholars most cited alongside Michael Burchmore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Hit paper breakdown → | 2002 | 1509 |
| 2 | 2001 | 145 | |
| 3 | 2001 | 145 | |
| 4 | 2002 | 112 | |
| 5 | Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). | 1999 | 39 |
| 6 | 1994 | 35 | |
| 7 | 2023 | 19 | |
| 8 | 2001 | 11 | |
| 9 | 1999 | 8 |
About Michael Burchmore
Michael Burchmore is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Pharmacology and Pulmonary and Respiratory Medicine, having authored 9 papers that have together received 2.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (4 papers), Peptidase Inhibition and Analysis (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Pharmacological Receptor Mechanisms and Effects (1 paper), Inflammatory mediators and NSAID effects (1 paper), Analytical Methods in Pharmaceuticals (1 paper) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Oncology (1.4k citations), Radiology, Nuclear Medicine and Imaging (687 citations), Cancer Research (273 citations), Immunology and Allergy (63 citations) and Genetics (83 citations). Michael Burchmore has collaborated with scholars based in United States and Canada. Frequent co-authors include Dennis J. Slamon, Maureen Murphy, Steven Shak, Debu Tripathy, Melody Cobleigh, Louis Fehrenbacher, William Novotny, Lyndsay N. Harris, Charles L. Vogel and Stanford J. Stewart. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Oncology, Orthopedics and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.